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3Condensation: When evaluating predictors of misoprostol early pregnancy 
loss treatment success, mifepristone pretreatment is a better predictor than 
baseline clinical factors, including vaginal bleeding or parity.
Short title: Predictors of misoprostol miscarriage treatment success
AJOG at a Glance:
A. Why was this study conducted?
 To evaluate characteristics associated with treatment success in 
women receiving medical management of early pregnancy loss 
(EPL).
B. What are the key findings?
 Mifepristone pretreatment and nonsmoking status were the only 
predictors of treatment success in our population 
 Previously described clinical predictors of success with 
misoprostol alone were not validated in our population, nor did 
we identify important clinical factors that would support the use 
of misoprostol without mifepristone for EPL management.
C. What does this study add to what is already known?
 We evaluated previously described predictors of EPL medical 
treatment success in a diverse cohort, including patients 
receiving mifepristone pretreatment.
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4 Pretreatment with mifepristone is a more useful intervention 
than considering baseline clinical characteristics to maximize 
treatment success in women undergoing misoprostol treatment 
of EPL.
Key words: early pregnancy loss, medical management, mifepristone, 
miscarriage, misoprostol
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5Abstract
Background: Early pregnancy loss (EPL) is a common event in the first 
trimester, occurring in 15-20% of recognized pregnancies. A common 
evidence-based medical regimen for EPL management uses the 
prostaglandin E1 analogue misoprostol 800 mcg self-administered vaginally. 
The clinical utility of this regimen is limited by suboptimal effectiveness in 
women with a closed cervical os, with 29% of women with EPL requiring a 
second dose after three days, and 16% eventually requiring a uterine 
aspiration procedure.
Objectives: To evaluate characteristics associated with treatment success 
in women receiving medical management with mifepristone-misoprostol or 
misoprostol alone for early pregnancy loss (EPL).
Study Design: We performed a planned secondary analysis of a randomized
trial comparing mifepristone-misoprostol to misoprostol alone for EPL 
treatment. The published prediction model for success of single-dose vaginal
misoprostol included the following variables: active bleeding, type of EPL 
(anembryonic pregnancy or embryonic/fetal demise), parity, gestational age,
and treatment site; previous significant predictors were vaginal bleeding 
within the past 24 hours, and parity of 0 or 1 versus higher. We first 
assessed in bivariate analyses if these characteristics predicted differential 
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6proportions of women with success or failure; given the small proportion of 
treatment failures in the combined treatment arm, both arms were combined
for analysis. We then performed a logistic regression analysis to assess the 
effect of these factors collectively in each of the two treatment groups 
separately as well as in the full cohort as a proxy for the combined treatment
arm. We tested the ability of characteristics previously associated with 
misoprostol success to discriminate successful from failed treatment using 
receiver-operating characteristic curves. We calculated the area under the 
curve (AUC) to quantify the ability of the score to discriminate between 
treatment success or failure in each treatment arm as well as in the entire 
cohort. Using multivariable logistic regression, we then assessed our study 
population for other predictors of treatment success in both treatment 
groups, with and without mifepristone.
Results: This analysis includes all 297 evaluable subjects in the primary 
study, including 148 in the mifepristone-misoprostol combined and 149 in 
the misoprostol-alone groups. Among women who had vaginal bleeding at 
the time of treatment, 15/17 (88%) in the mifepristone-misoprostol combined
group and 12/17 (71%) of those in the misoprostol-alone group expelled the 
pregnancy. Among women with a parity of 0 or 1, 94/108 (87%) in the 
mifepristone-misoprostol combined group, and 66/95 (69%) of those in the 
misoprostol-alone group expelled the pregnancy. These clinical 
characteristics did not predict success above chance alone in the combined 
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7cohort (AUC=0.56, 95% CI 0.48-0.64). No other baseline clinical factors 
predicted treatment success in the misoprostol-alone or mifepristone 
pretreatment arms individually. In the full cohort, the only significant 
predictors of treatment success were mifepristone pretreatment (aOR 2.51, 
95% CI 1.43-4.43), and smoking (aOR 2.15, 95% CI 1.03-4.49). 
Conclusion: No baseline clinical factors predict success in women 
undergoing medical management of EPL with misoprostol. Adding 
mifepristone to the EPL medical management regimen improves treatment 
success and should be used regardless of baseline clinical characteristics.
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8Main Text
Introduction
Early pregnancy loss (EPL) is a common event in the first trimester of 
pregnancy, occurring in 15-20% of recognized pregnancies (1). Both 
providers and patients have shown an interest in pursuing nonsurgical 
treatment options for EPL (2). A common evidence-based EPL medical 
management regimen uses the prostaglandin E1 analogue misoprostol 800 
mcg self-administered vaginally to facilitate pregnancy tissue expulsion (3-
5). The clinical utility of this regimen is limited by suboptimal effectiveness in
women with a closed cervical os (6), with 29% of women with EPL requiring a
second treatment dose after three days and 16% eventually requiring a 
uterine aspiration procedure (3, 7). 
In 2018, we reported the results of a multicenter trial designed to 
evaluate if mifepristone pretreatment could improve misoprostol 
effectiveness (8). We included 297 women with anembryonic gestation or 
embryonic/fetal demise to receive misoprostol vaginally with or without 
mifepristone pretreatment; treatment success (complete pregnancy 
expulsion) rates with one misoprostol dose and mifepristone pretreatment 
(84%, 95% CI 77-90%) was higher than with misoprostol alone (67%, 95% CI 
59-75%)(9). Unfortunately, these positive findings may not translate to a 
shift in current clinical care in the U.S. because mifepristone access is 
restricted under current FDA requirements, making mifepristone difficult to 
access in many locations (10). Accordingly, we sought to identify 
8
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
9characteristics within our study population that could be predictive of 
improved success for women who may be offered misoprostol alone. 
A secondary analysis of a U.S. multicenter study performed in the mid-
2000s identified basic clinical characteristics that predicted treatment 
success with EPL medical management from 5-12 weeks gestational age (7). 
The primary predictors demonstrated in this model, reported in 2006, were 
vaginal bleeding and parity of 0 or 1. Our primary objective was to evaluate 
if these previously identified clinical characteristics are associated with 
greater success in the misoprostol-alone arm of our trial. In addition, we 
sought to identify characteristics that predict success in each arm of the 
study and in the combined cohorts to help inform treatment decision making 
for women deciding between medical and surgical EPL management. 
Materials and Methods
We performed this planned secondary analysis to evaluate clinical predictors
previously associated with single-dose vaginal misoprostol EPL treatment 
success (7), with and without mifepristone pretreatment. The results of the 
primary study of EPL medical management have been previously reported
(8). In brief, we enrolled 300 women in a multi-center, randomized, single-
masked trial to compare the effectiveness of combination treatment 
(mifepristone 200 mg orally followed 24 hours later by misoprostol 800 mcg 
vaginally) to usual treatment (misoprostol 800 mcg vaginally). The final 
evaluable cohort included 148 and 149 women in the two treatment groups, 
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respectively. The trial included women 18 years and older diagnosed with a 
nonviable intrauterine pregnancy (anembryonic gestation or embryonic/fetal 
demise) between 5 and 12 weeks gestation, and excluded women with an 
incomplete or inevitable abortion, and women clinically ineligible for EPL 
medical management (8). Participants were recruited from a range of 
practice settings, including those offering providing services in obstetrics and
gynecological services and primary care services (Table 1). The primary 
outcome was complete expulsion of the gestational sac by the first follow-up 
visit (24h after misoprostol use, range days 2-5) without further intervention 
over the 30-day study period. Women who did not expel the gestational sac 
could opt for a second misoprostol dose, surgical aspiration or expectant 
management. The trial was registered with Clinicaltrials.gov, protocol 
number NCT02012491. The primary study had greater than 90% power to 
detect a ratio of 2 for the risk of failure in the mifepristone pretreatment arm
compared to the misoprostol-alone arm.
For this analysis, we first attempted to validate previously described 
predictors of success of medical management of EPL with a single dose of 
vaginal misoprostol alone. The published prediction model (7) for single-dose
vaginal misoprostol included the following variables: active bleeding, type of 
EPL (anembryonic pregnancy or embryonic/fetal demise), parity, gestational 
age, and treatment site; previous significant predictors were vaginal 
bleeding within the past 24 hours, and parity of 0 or 1 versus higher. We 
10
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
11
hypothesized that the sensitivity of the combined predictive markers to 
predict success would be 90% +/-5%. 
To apply the previously published prediction rule to our population, we 
computed a weighted score by using the log-odds ratios of each predictor 
listed in the published multivariable model (active bleeding, type of EPL, 
parity, gestational age, and treatment site). We summed risk factor weights 
for each subject, based on whether or not the individual participant 
possessed the clinical characteristic(s). We created receiver operating 
characteristic curves (ROC) and calculated the area under the curve (AUC) to
quantify the ability of the score to discriminate between treatment success 
or failure in each arm as well as in the entire cohort. The AUC is a summary 
of diagnostic accuracy: if the AUC equals 0.5, the ROC curve corresponds to 
random chance; if the AUC equals 1, the diagnostic model has perfect 
accuracy (11). We grouped the scores into deciles, to investigate differences 
in success by summed weights and to assess goodness-of-fit. We used 
logistic regression to predict the probability of successful management 
based on score decile (12).
Next, we assessed in bivariate analyses if these characteristics 
predicted differential proportions of women with success or failure using 
Pearson χ2 analyses. Given the small proportion of treatment failures in the 
combined treatment arm, the arms were combined for analysis.  We then 
performed a logistic regression analysis to assess the effect of these factors 
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collectively in each of the two treatment groups separately as well as in the 
full cohort as a proxy for the combined treatment arm.
Lastly, we assessed the remaining clinical predictors of success of 
medical management of EPL in the full cohort of participants (who used 
misoprostol with or without mifepristone), as well as in each of the treatment
arms separately. We performed bivariate analyses using Pearson χ2 analyses
or Wilcoxon rank sum tests as appropriate, comparing women in the full 
cohort of participants who had success or failure of medical management of 
EPL, by demographic and clinically relevant factors. We evaluated treatment 
success in a multivariable logistic regression analysis by performing stepwise
backwards selection for any covariates from Table 1 with a P ≤0.2 and the 
set of 2006 predictors (12). 
Results
This analysis includes all 297 evaluable subjects in the primary study, 
including 148 in the mifepristone-misoprostol combined treatment and 149 
in the misoprostol-alone groups.   Bivariate analysis of predictors of success 
for the full cohort are presented in Table 1. Using the combined predictive 
variables of vaginal bleeding and parity of 0 or 1, we had 90%+/-3% power 
to detect success with 90% sensitivity.
Previously described predictors of success of medical management 
with misoprostol did not differ by randomization group (Table 2). When we 
applied the predictors to our population using risk factor weights to create a 
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risk score, the odds ratio for increased success by decile in the full cohort 
was 1.08 (95% CI 0.98, 1.18; Figure 1). The area under the receiver 
operating characteristics curve using the score based on the predictors was 
0.56 (95% CI 0.48-0.64) in the full cohort (Figure 1).
Bivariate predictors of medical management success in the full cohort 
included non-smoker status (p=0.01), pain during periods (p=0.19), and 
randomization group (p=0.001; Table 1). In the multivariable logistic 
regression model, both mifepristone pretreatment (P=0.001) and non-
smoking status (p=0.04) remained significant in the full cohort. However, 
non-smoking status was not significant in the model for the misoprostol-
alone group (p=0.06) or mifepristone pretreatment group (p=0.44).  The 
area under the receiver operating characteristics curve was 0.64 (95% CI 
0.56-0.7) for the full cohort.
Discussion
1. Principal findings
In this planned secondary analysis of a randomized controlled trial 
comparing the efficacy of pretreatment with mifepristone followed by 
misoprostol versus misoprostol alone for EPL management, we found no 
clinical or medical history predictors of treatment success, except for 
nonsmoking status. When restricting our analysis to the treatment group 
that received misoprostol alone (the treatment group that might benefit 
most from a described “phenotype” for success), previously described 
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clinical predictors for success, parity and current bleeding, did not predict 
success. 
2. Results in context
We modeled this research on a prior U.S. multicenter study of clinical 
predictors for success in a population of 491 women who received 
misoprostol alone for EPL management (7). In that study, authors found that 
vaginal bleeding within the past 24 hours and nulliparity or low parity 
predicted success with a single misoprostol dose. Nulliparous or primiparous 
women with bleeding in the preceding 24 hours had success rates of 79% 
and 77%, respectively. Of note, overall success of medical management of 
EPL (including up to 2 doses of misoprostol up to 30 days after initial 
management), was 95% in women who had lower abdominal pain and 
bleeding in the past 24 hours [7]. Our current study was focused on 
assessing treatment success after one misoprostol dose in accordance with 
patient preferences [2]; we did not identify clinical characteristics associated 
with successful expulsion in either the misoprostol-only or mifepristone 
pretreatment arms.
Our inability to validate previously determined predictors of treatment 
success may be partially attributable to differences in the study populations. 
The study sites differed from the 2006 study that included 4 sites all on the 
United States east coast (New York, Philadelphia, Pittsburgh and Miami) (7), 
while our current study included subjects from New York, Philadelphia and 
Sacramento, with 26% of participants from California (8). However, the 
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proportion of women with treatment success in each group in our study did 
not vary by site.  Perhaps more important are differences in the presence of 
bleeding between the two studies. In the 2006 study (1), 64% had vaginal 
bleeding within the 24 hours prior to treatment and 88% of these women 
with vaginal bleeding had success with up to 2 doses of misoprostol. In our 
study, only 12% of women had any bleeding prior to randomization (8). It is 
possible that misoprostol alone is an appropriate treatment regimen for 
women with EPL who are already having bleeding, but the small proportion 
of women with bleeding in our study diminished our ability to recognize this 
association. Alternatively, pretreatment with mifepristone in a population of 
women who are already bleeding is unlikely to have adverse effects and may
improve success rates. 
3. Clinical and research implications 
In our population, self-reported non-smoking status predicted 
treatment success in the full cohort, although this risk factor did not achieve 
significance in either group separately. The reason for this finding is unclear 
and should be interpreted with caution; the association was based on a small
cohort of smokers (13% of the total population) and could represent some 
other unmeasured variable. Chronic nicotine may decrease uterine blood 
flow (13), and can prolong gestation and inhibit cervical ripening in rats, 
possibly by suppression of an anti-inflammatory response (14). The 
pathophysiology of this pathway in humans is not elucidated. The 2006 study
did not include smoking in its assessment of clinical predictors of success. 
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Smoking prevalence has decreased in the United States (15) but remains 
prevalent in other countries (16); the interplay between smoking and EPL 
management strategies may deserve further study.
4. Strength and limitations
The strength of this planned secondary analysis includes its diverse 
population with prospective data collection from a randomized controlled 
trial. We were limited by the small proportion of treatment failures in the 
mifepristone pretreatment group. Although we analyzed for baseline clinical 
predictors for success in this group, a larger sample size would have allowed 
for more power to detect individual predictors. Our study sample had 
differing clinical characteristics as compared with the 2006 comparison 
study, which may have affected the validation of prior predictors of 
treatment success with misoprostol alone. Future cohort studies examining a
larger population of women receiving combined treatment with mifepristone 
and misoprostol for EPL may identify important baseline clinical predictors 
for treatment success. 
5. Conclusion
In summary, we found that previously described clinical predictors do 
not support large effects of particular patient characteristics having similar 
success using misoprostol without mifepristone pretreatment, nor we were 
able to identify additional baseline clinical factors that would support the use
of misoprostol without mifepristone for EPL management. Given the 
improvement in success with mifepristone pretreatment discovered in the 
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primary study, the results of this secondary analysis further support the 
recommendation that all women who desire misoprostol management of EPL
should receive pretreatment with mifepristone to maximize the likelihood of 
success.
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Figure title and legend
Figure title: Receiver operating characteristics curve of success using the 
2006 model
Figure legend: Receiver operating characteristics curve for the full cohort 
(AUC 0.56 95% CI 0.48-0.64) applying the 2006 predictor model for single-
dose misoprostol success of medical management of EPL. 95% confidence 
interval contains 0.5 and thus the test is no different than random chance.
(7)
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Tables
Table 1: Demographic and clinical characteristics by failure or success of 
medical management of early pregnancy loss
  Full 
cohort
N=297
Failur
e
n=73
Success
n=224
p-value
Median age (years) 31 (26-
35)
30 (25-
35)
31 (26-35) 0.5
Mean BMI (kg/m2) 27.4 
(23.2-
32.5)
27.8 
(23.8-
32.3)
27.3 (23.0-
32.7)
0.64
Race 0.60
     Black or African 
American
131 (44) 38 (29) 93 (71)
     White 108 (36) 25 (23) 83 (77)
     Mixed/more than one
race
30 (10) 6 (20) 24 (80)
     Asian 20 (7) 3 (15) 17 (85)
     Native 
Hawaiian/Pacific 
Islander
2 (1) 0 (0) 2 (100)
     Other/unknown 6 (2) 1 (117) 5 (83)
Ethnicity 0.51
     Non-Hispanic or Non-
Latina
219 (74) 56 (26) 163 (74)
     Hispanic or Latina 78 (26) 17 (22) 61 (78)
Smoking* 0.01
     No 259 (87) 57 (22) 202 (78)
     Yes 37 (13) 15 (41) 22 (59)
Prior early pregnancy 0.87
20
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loss
     No 193 (65) 48 (25) 145 (75)
     Yes 104 (35) 25 (24) 79 (76)
Prior induced abortion 0.40
     No 199 (67) 46 (23) 153 (77)
     Yes 98 (33) 27 (28) 71 (72)
Prior medical abortion* 0.23
     No 274 (93) 69 (25) 205 (75)
     Yes 22 (7) 3 (1) 19 (86)
Prior surgical abortion* 0.21
     No 202 (68) 45 (23) 157 (78)
     Yes 93 (32) 27 (29) 66 (71)
Parity 0.27
     0 114 (38) 24 (21) 90 (79)
     1 or more 183 (62) 49 (27) 134 (73)
Pain during periods 0.19
     No pain 56 (19) 21 (38) 35 (62)
     Very little 76 (26) 14 (18) 62 (82)
     Some 84 (28) 20 (24) 64 (76)
     Quite a bit 35 (12) 9 (26) 26 (74)
     Very much 39 (13) 8 (21) 31 (79)
     Worst pain 7 (2) 1 (14) 6 (86)
Gestational age 0.75
     <7 Weeks 107 (36) 27 (25) 80 (75)
     7-8 6/7 Weeks 144 (48) 33 (23) 111 (77)
     9-12 6/7 Weeks 46 (15) 13 (28) 33 (72)
Diagnosis 0.52
     Embryonic/fetal 
demise
220 (74) 52 (24) 168 (76)
     Anembryonic 
gestation
77 (26) 21 (27) 56 (73)
Method of pregnancy 
conception
0.13
     Spontaneous 276 (94) 71 (26) 205 (74)
     Assisted 
reproductive 
technologies
16 (5) 1 (6) 15 (94)
Active bleeding 0.74
     No 288 (77) 56 (25) 172 (75)
21
22
     Yes 34 (11) 7 (21) 27 (79)
     Not assessed 35 (12) 10 (29) 25 (71)
Rh status 0.94
     Rh- 24 (8) 6 (25) 18 (75)
     Rh+ 268 (92) 65 (24) 203 (76)
Uterine tenderness* 0.80
     No 257 (87) 62 (24) 195 (76)
     Yes 11 (4) 3 (27) 8 (73)
     Not assessed 27 (9) 8 (30) 19 (70)
Randomization arm 0.001
     Misoprostol alone 149 (50) 49 (33) 100 (67)
     Mifepristone 
pretreatment
148 (50) 24 (16) 124 (84)
Site 0.099
     University of 
Pennsylvania
160 (54) 47 (29) 113 (71)
     University of 
California, Davis
76 (26) 13 (17) 63 (83)
     Albert Einstein 
College of Medicine
61 (21) 13 (21) 48 (79)
Data are presented as n (%), mean (standard deviation), or median 
(interquartile range). Column percentages are presented for the full cohort; 
row percentages are presented otherwise.
* Data missing for Smoking (n=1), Prior medical abortion (n=1), Prior 
surgical abortion (n=2), Rh status (n=5), Uterine tenderness (n=2), Method 
of pregnancy conception (3)
22
389
390
391
392
393
394
23
Table 2: Distribution by treatment group of variables included in the 
previously-described predictor model* for single-dose misoprostol success of 
early pregnancy loss management
  Full 
cohort
Misopros
tol alone
Mifeprist
one 
pretreat
ment
p-
value
Active bleeding 0.65
     No 288 (77) 117 (79) 111 (75)
     Yes 34 (11) 17 (11) 17 (11)
     Not Assessed 35 (12) 15 (10) 20 (14)
Diagnosis 0.67
     Embryonic/fetal 
demise
220 (74) 112 (75) 108 (73)
     Anembryonic 
gestation
77 (26) 37 (25) 40 (27)
Parity 0.19
     0 114 (38) 51 (34) 63 (43)
     1 89 (30) 44 (30) 45 (30)
     2+ 94 (32) 54 (36) 40 (27)
Gestational age 0.75
     <7 Weeks 107 (36) 27 (37) 80 (36)
     7-8 6/7 Weeks 144 (48) 33 (45) 111 (50)
     9-12 6/7 Weeks 46 (15) 13 (18) 33 (15)
Site 0.99
     University of   
Pennsylvania
160 (54) 80 (54) 80 (54)
     University of    
California, Davis
76 (26) 38 (26) 38 (26)
     Albert Einstein 
College of Medicine
61 (21) 31 (21) 30 (20)
Data are presented as n (%).
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* from Creinin MD, Huang X, Westhoff C, Barnhart K, Gilles JM, Zhang J, et al. 
Factors related to successful misoprostol treatment for early pregnancy 
failure. Obstet Gynecol. 2006;107(4):901-7.
24
399
400
401
Table 3: Final multivariable model for within-study clinical predictors of 
success of medical management of early pregnancy loss
  OR 95% CI p-
v
a
l
u
e
aOR* 95% CI p-
v
a
l
u
e
Smoking  
     Yes refere
n
t
  referen
t 
     No 2.41 1.18-
4
.
9
6
0.02 2.15 1.03-
4.
49
0.04
Randomization arm  
     Misoprostol alone refere
n
t
 
  referen
t 
     Mifepristone 
pretreatment
2.53 1.45-
4
.
0.001 2.51 1.43-
4.
43
0.001
402
403
404
26
4
1
*Adjusted for smoking and treatment arm
OR: odds ratio; CI: confidence interval; aOR: adjusted odds ratio
26
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406
407
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